FTSE 100 news / Companies and sectors / GSK / GSK selects Wave hepatology candidate
GSK selects Wave hepatology candidate
+4.8 positive
GSK advanced a Wave siRNA liver candidate, triggering a $12m milestone.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| AD HOC NEWS | 2 | +5.4 |
| Simply Wall Street | 1 | +6.7 |
| Yahoo Finance | 1 | +6.7 |
| European Biotechnology Magazine | 1 | +6.7 |
| AllSci | 1 | +6.0 |
| Fierce Biotech | 1 | +5.8 |
| TipRanks | 1 | +5.8 |
| Kalkine Media | 1 | +5.5 |
| Investing.com UK | 1 | +5.0 |
| genomeweb.com | 1 | +5.0 |
| Investing News Network | 1 | +5.0 |
| Quiver Quantitative | 1 | +5.0 |
| Stock Titan | 1 | +4.7 |
| Seeking Alpha | 1 | +3.3 |
| Traders Union | 1 | −5.0 |
Day by day
Friday 9 October 2026
GSK shares fell more than 2% after adding a new hepatology candidate.
- −5.0 GSK shares drop more than 2% after adding a new hepatology candidate amid persistent selling
Shares fall over 2% despite new hepatology candidate
Thursday 8 October 2026
GSK added a new hepatology candidate to its pipeline.
- +6.7 GSK (LSE:GSK) Adds A New Hepatology Candidate, Is The 18% Undervaluation Case Intact?
New hepatology candidate; shares seen as undervalued. - +6.7 GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
Two research partnerships deepen the drug pipeline. - +6.7 GSK stock adds a liver candidate to its pipeline
Adds a liver candidate to its pipeline.
Friday 2 October 2026
GSK advanced a Wave siRNA liver candidate, paying Wave a $12m milestone.
- +6.7 GSK adds liver candidate from Wave RNA partnership
GSK adds liver candidate from Wave partnership. - +6.0 Wave lands USD 12m as GSK advances SpiNA siRNA program
GSK advances siRNA programme, triggering milestone payment to Wave. - +5.5 How Is GSK (LSE:GSK) Stock Reacting This Week To Its Wave Life Sciences Liver Candidate?
Wave liver candidate progress and share reaction.
Thursday 1 October 2026
GSK advanced a Wave siRNA liver candidate, triggering a $12m milestone.
- +5.8 GSK continues to stock up on Wave's RNA drugs with liver-focused program
GSK building RNA drug portfolio with liver program. - +5.8 Wave Life announces GSK’s selection of siRNA program to transition to GSK
GSK advances siRNA program from Wave collaboration. - +5.0 GSK selects Wave Life Sciences hepatology candidate By Investing.com
GSK selects Wave hepatology candidate. - +5.0 GSK Taps Wave Life Sciences’ siRNA Program, Triggering $12M Milestone Payment
GSK taps Wave siRNA program, pipeline progress. - +5.0 Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
GSK selects siRNA program for further development. - +5.0 Wave Life Sciences Announces GSK Advances Hepatology Candidate from SpiNA siRNA Collaboration
GSK advances hepatology candidate from collaboration. - +4.7 GSK selected a liver candidate for development, triggering $12 million for Wave.
GSK picks liver candidate for development. - +4.2 Wave Life Sciences stock gets a USD 12.0 million GSK boost
GSK selects Wave program, pipeline progress; milestone paid by GSK. - +3.3 Wave to receive $12M milestone from GSK (WVE:NASDAQ)
Milestone payable to Wave reflects GSK program progress.